Sarepta Therapeutics, Inc. — Form 10-Q
Filed August 5, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 12/100
What the filing says
Sarepta Therapeutics filed template agreements for its 2026 Equity Incentive Plan, establishing standard forms for stock option grants (with 4-year vesting: 25% year 1, then 1/48 monthly) and restricted stock unit grants (25% annual vesting over 4 years). The filing contains no dollar amounts, participant names, or grant counts—only boilerplate legal terms and conditions for future equity awards. This is a plan framework document with no specific grants disclosed.
Why this rating
Routine equity plan documentation; no actual grants, dollar values, or material business changes disclosed. Standard administrative filing.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.